Antiphospholipid-protein antibodies: Clinical use of laboratory test results (identification, predictive value, treatment)

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 358-367

  Triplett, Douglas A ^a  

^a BALL MEMORIAL HOSPITAL   (United States)

Author keywords

Antibodies; Anticardiolipin; Anticoagulant; Lupus; Recurrent Abortion; Thrombosis; Glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ABORTION; CONFERENCE PAPER; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; INFECTION; ISOANTIBODIES; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEOPLASMS; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; PROTEIN C; RISK; THROMBOSIS;

EID: 0029853896     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217317     Document Type: Article

References (44)

1. Triplett, D.A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995;78:1-31.
2. Roubcy RAS. Autoantibodics to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-2867.
3. Brandt JT, Triplett DA, Alving B. Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Hacmost 1995;74:1185-1190.
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: B2 Glycoprotein I (apolipoprotcin H). Proc Natl Acad Sci USA 1990;87:4120-4124.
5. Galli M. Comfurius P, Maassen C. Hemkcr HC deBaets MH. van Breda-Vriesman PJC, Barbui T. Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990;335:1544-1547.
6. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize p2‘Glycoprotein I in the absence of phospholipid. J Immunol 1995;154:954-960.
7. Al-Saeed A, Makris M. Malia RG, Preston FE, Greaves M. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br J Haematol 1994;88:845-848.
8. Prieto J. Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B. Sangro B. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996;23:199-204.
9. Facer CA. Agiostratidou G. High levels of anti-phospholipid antibodies in uncomplicated and severe plasmodium falciparum and P. vivax malaria. Clin Exp Immunol 1994:95:304-309.
10. Triplett DA. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost 1995;74:329-337.
11. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341-344.
12. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Ann Rev Med 1995;47:533-553.
13. Asherson RA, Khamashta MA. Ordi-Ros J. Derksen RH. Machin SJ, Barquinero J. Outt HH, Harris EN, Vilardell-Torres M. Hughes GR. The ‘primary’ antiphospholipid syndrome: major clinical and serological features. Medicine 1989;68:366-374.
14. Mackworth-Young CG. Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989:48:362-367.
15. Harris, E.N. Baguley, E. Asherson, R.A. Hughes, G.R.V. Clinical and serological features of the antiphospholipid syndrome (APS). Br J Rheumatol 1987:26:19 (abstract).
16. Triplett DA. New diagnostic strategies for lupus anticoagulants and antiphospholipid antibodies. Haemostasis 1994;24:155-164.
17. Schjetlein R. Sletnes KE, Wisloff F. A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thromb Res 1993:69:239-250.
18. Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral pattern. Br J Haematol 1978:40:143-151.
19. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986:68:869-874.
20. Johns AS, Chamley L, Ockelford PA, Pattison NS, McKay EJ, Corkill M, Hart H. Comparison of tests for the lupus anticoagulant and antiphospholipid antibodies in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:523-526.
21. Triplett DA, Brandt JT, Kaczor D. Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983:79:678-682.
22. Triplet! DA. Barna LK. Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-793.
23. Harris EN. Gharavi AE. Boey ML. Patel BM, Mackworth-Young, CG, Loizou S. Hughes GR. Anticardiolipin antibodies: detection by radioimmunoassay and association with recurrent cardiovascular events. Lancet 1983:2:1211-1214.
24. Malsuda J. Saitoh N. Gohchi K. Gotoh M. Tsukamoto M. Distinguishing β2 Glycoprotein 1 dependent (systemic lupus erythematosus type) and independent (syphilis type) anticardiolipin antibody with Tween 20. BrJ Haematol 1993;85:799-802.
25. Triplett DA, Stocker KF. Unger GA. Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993:70:925-931.
26. Stewart MW, Etches WS, Russeu AS. Percy JS, Johnston CA, Chew CK, Gordon PA. Detection of antiphospholipid antibodies by How cytometry: rapid detection of antibody isotype and phospholipid specificity. Thromb Haemost 1993:70:603-607.
27. Frost SJ, Chakraborty J. Firth GB. Novel homogeneous liposomal immunoassay for colorimetric estimation of serum IgG anticardiolipin antibodies. Clin Chem 1996:42:874-876.
28. Puurunen M, Vaatala O. Julkanen H. Aho K. Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopath 1996:80:16-22.
29. Katano K, Aoki K, Sasa H. Ogasawara M, Matsuura E, Yagami Y. β2 Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant woman. Hum Reprod 1996:11:509-512.
30. Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. AJRI 1989:20:52-67.
31. Triplett DA. Antiphospholipid antibodies and thrombosis: a consequence, coincidence, or cause? Arch Pathol Lab Med 1993:117:78-88.
32. Derksen RHWM, Hasselaar O. Blokzijl L, Meyling FHJG, De Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988;47:364-371.
33. Galli M, Finazzi G. Bevers EM. Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and 02 Glycoprotein 1-dependent antiphospho lipid antibodies. Blood 1995;86:617-623.
34. Ginsburg KS, Liang MH. Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Int Med 1992;117:997-1002.
35. Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993;78:313-318.
36. Vaarala O, Puurunen M. Manttari M. Manninen V. Aho K. Palosuo T. Antibodies to prothrombin imply a risk of myocardial-infarction in middle-aged men. Thromb Haemost 1996;75:456-459.
37. Long AA. Ginsburg JS, Brill Edwards, Johnston M, Turner C, Denburg JA. Bensen WG. Cividino A, Andrew M. Hirsh J. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross sectional study. Thromb Haemost 1991;66:520-524.
38. Vermylen J. Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 1992;120:10-12 (editorial).
39. Oosting JD. Derksen RHWM. Bobbink IWG. Hackeng TM. Bouma BN. DeGroot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S. An explanation for their pathogenic mechanism? Blood 1993;81:2618-2625.
40. Nguyen P. Reynaud J. Pouzol P, Munzer M. Richard O. Francois P. Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatr 1994;153:646-649.
41. D'Angelo A. Della Valle P. Crippa L, Grimaloi L, Meschi F, Vigano-D'Angelo S. Severe thromboembolic disease due to autoimmune deficiency of vitamin K-dependent protein S. Thromb Res 1982:65 [suppl]:S91.
42. Smirnov MD. Triplett DT. Comp PC. Esmon NL. Esrnon CT, On the role of phosphatidylethano-lamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995;95:309-316.
43. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 43. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426-2432.
44. Potzsch B. Kawamura H. Preissner KT, Schmidt M, Seelig C. Muller-Bcrghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995;125:56-65.